Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1

Neuro-Oncology

Volumn 15, Issue 2, 2013, Pages 135-147

  Kolberg, Matthias ^a,b   Høland, Maren ^a,b   Agesen, Trude H ^a,b   Brekke, Helge R ^a,b   Liestøl, Knut ^c   Hall, Kirsten S ^a   Mertens, Fredrik ^d   Picci, Piero ^e   Smeland, Sigbjørn ^a   Lothe, Ragnhild A ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Metaanalysis; MPNST; Neurofibromatosis; NF1

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; HUMAN; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REVIEW; SURVIVAL RATE;

HUMANS; META-ANALYSIS AS TOPIC; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; PROGNOSIS; SURVIVAL RATE;

EID: 84875702670     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos287     Document Type: Review

References (109)

1. von Recklinghausen F. Über die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. Festschrift für Rudolf Virchow. Berlin, Germany: Hirschwald, 1882; 138.
2. Harbitz F. Multiple neurofibromatosis (von Recklinghausen's disease). Arch Int Med. 1909;3:32-65.
3. Hosoi K. Multiple neurofibromatosis (von Recklinghausen's disease). Arch Surg. 1931;22:258-281.
4. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62:1573-1577. (Pubitemid 34407825)
5. Perrin RG, Guha A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2004;15:203-216. (Pubitemid 38737290)
6. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006-2021. (Pubitemid 16113778)
7. Fletcher CDM, Unni KK, Mertens F. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press, 2002.
8. Weiss SW, Goldblum Jr. Enzinger and Weiss's Soft Tissue Tumors. 5th edn. St. Louis, MO: Mosby Elsevier, 2008.
9. Mertens F, Dal Cin P, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: A report of the CHAMP study group. J Pathol. 2000;190:31-38. (Pubitemid 30053350)
10. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: Molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340-349. (Pubitemid 351358582)
11. Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2008;19:533-543.
12. Widemann BC. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009;11:322-328.
13. Ferrari A, Miceli R, Rey A, et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. Eur J Cancer. 2011;47:724-731.
14. McCaughan JA, Holloway SM, Davidson R, Lam WW. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet. 2007;44:463-466. (Pubitemid 47056874)
15. Evans DG, O'Hara C, Wilding A, et al. Mortality in neurofibromatosis 1: In NorthWest England: An assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet. 2011;19:1187-1191.
16. Masocco M, Kodra Y, Vichi M, et al. Mortality associated with neurofibromatosis type 1: A study based on Italian death certificates (1995-2006). Orphanet J Rare Dis. 2011;6:11.
17. Barker D, Wright E, Nguyen K, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome-17. Science. 1987;236:1100-1102. (Pubitemid 17113253)
18. Messiaen LM, Callens T, Mortier G, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000;15:541-555. (Pubitemid 30368440)
19. Upadhyaya M, Kluwe L, Spurlock G, et al. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat. 2008;29:74-82.
20. Bottillo I, Ahlquist T, Brekke H, et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol. 2009;217:693-701.
21. Lothe RA, Karhu R, Mandahl N, et al. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res. 1996;56:4778-4781. (Pubitemid 26338084)
22. Berner JM, Sorlie T, Mertens F, et al. Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: Studies of CDKN2A and other genes of the pRB pathway. Genes Chromosomes Cancer. 1999;26:151-160. (Pubitemid 29416440)
23. Schmidt H, Wurl P, Taubert H, et al. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer. 1999;25:205-211. (Pubitemid 29266689)
24. Brekke HR, Ribeiro FR, Kolberg M, et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol. 2010;28: 1573-1582.
25. Sordillo PP, Helson L, Hajdu SI, et al. Malignant schwannoma-clinical characteristics, survival, and response to therapy. Cancer. 1981;47:2503-2509. (Pubitemid 11127646)
26. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: The Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23:8422-8430.
27. Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in malignant peripheral nerve sheath tumours: A comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma. 2009;2009:756395.
28. Okada K, Hasegawa T, Tajino T, et al. Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: A multi-institution TMTS study of 56 cases in northern Japan. Ann Surg Oncol. 2007;14:597-604. (Pubitemid 46175305)
29. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: Prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065-1074. (Pubitemid 44291156)
30. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014-1022.
31. Yu J, Deshmukh H, Payton JE, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res. 2011;17:1924-1934.
32. Brekke HR, Kolberg M, Skotheim RI, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol. 2009;11:514-528.
33. Storlazzi CT, Brekke HR, Mandahl N, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol. 2006;209:492-500. (Pubitemid 44194564)
34. Longhi A, Errani C, Magagnoli G, et al. High grade malignant peripheral nerve sheath tumors: Outcome of 62 patients with localized disease and review of the literature. J Chemother. 2010;22:413-418.
35. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: Comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006;6:50.
36. Stucky CCH, Johnson KN, Gray BA, et al. Malignant peripheral nerve sheath tumors (MPNST): The Mayo Clinic experience. Ann Surg Oncol. 2012;19:878-885.
37. Demir HA, Varan A, Yalcn B, Akyuz C, Kutluk T, Buyukpamukcu M. Malignant peripheral nerve sheath tumors in childhood: 13 cases from a single center. J Pediatr Hematol Oncol. 2012;34:204-207.
38. D'Agostino AN, Soule EH, Miller RH. Primary malignant neoplasms of nerves (malignant neurilemomas) in patients without manifestations of multiple neurofibromatosis (von Recklinghausen's disease). Cancer. 1963;16:1003-1014.
39. D'Agostino AN, Soule EH, Miller RH. Sarcomas of the peripheral nerves and somatic soft tissues associated with multiple neurofibromatosis (von Recklinghausen's disease). Cancer. 1963;16:1015-1027.
40. Schmidt H, Taubert H, Meye A, et al. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. Cancer Lett. 2000;155:181-190. (Pubitemid 30259133)
41. White HR, Survival in malignant schwannoma. An 18-year study. Cancer. 1971;27:720-729.
42. Storm FK, Eilber FR, Mirra J, Morton DL. Neurofibrosarcoma. Cancer. 1980;45:126-129. (Pubitemid 10214966)
43. Ariel IM. Tumors of the peripheral nervous system. CA Cancer J Clin. 1983;33:282-299. (Pubitemid 13007396)
44. Bojsen-Møller M, Myhre-Jensen O. A consecutive series of 30 malignant schwannomas. Survival in relation to clinico-pathological parameters and treatment. Acta Pathol Microbiol Immunol Scand A. 1984;92:147-155. (Pubitemid 14090528)
45. Nambisan RN, Rao U, Moore R, Karakousis CP. Malignant soft tissue tumors of nerve sheath origin. J Surg Oncol. 1984;25:268-272. (Pubitemid 14111223)
46. Raney B, Schnaufer L, Ziegler M, Chatten J, Littman P, Jarrett P. Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958-1984. Cancer. 1987;59:1-5. (Pubitemid 17227385)
47. Greager JA, Reichard KW, Campana JP, DasGupta TK. Malignant schwannoma of the head and neck. Am J Surg. 1992;163:440-442. (Pubitemid 23065061)
48. Chang SM, Ho WL. Malignant peripheral nerve sheath tumor: A study of 21 cases. Zhonghua Yi Xue Za Zhi (Taipei). 1994;54:122-130.
49. Doorn PF, Molenaar WM, Buter J, Hoekstra HJ. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol. 1995;21:78-82.
50. DeCou JM, Rao BN, Parham DM, et al. Malignant peripheral nerve sheath tumors: The St. Jude Children's Research Hospital experience. Ann Surg Oncol. 1995;2:524-529.
51. Kunisada T, Kawai A, Ozaki T, Sugihara S, Taguchi K, Inoue H. A clinical analysis of malignant schwannoma. Acta Med Okayama. 1997;51:87-92. (Pubitemid 127457682)
52. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: Analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42:351-360. (Pubitemid 28502782)
53. Angelov L, Davis A, O'Sullivan B, Bell R, Guha A. Neurogenic sarcomas: Experience at the University of Toronto. Neurosurgery. 1998;43:56-64.
54. Ganju A, Roosen N, Kline DG, Tiel RL. Outcomes in a consecutive series of 111 surgically treated plexal tumors: A review of the experience at the Louisiana State University Health Sciences Center. J Neurosurg. 2001;95:51-60. (Pubitemid 32799772)
55. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-314. (Pubitemid 34526349)
56. Cashen DV, Parisien RC, Raskin K, Hornicek FJ, Gebhardt MC, Mankin HJ. Survival data for patients with malignant schwannoma. Clin Orthop Relat Res. 2004;426:69-73. (Pubitemid 39167110)
57. Watson MA, Perry A, Tihan T, et al. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol. 2004;14:297-303. (Pubitemid 39095992)
58. Holtkamp N, Atallah I, Okuducu AF, et al. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia. 2007;9:671-677. (Pubitemid 47328086)
59. Tabone-Eglinger S, Bahleda R, Cote JF, et al. Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma. 2008;2008:849156.
60. Endo M, Kobayashi C, Setsu N, et al. Prognostic significance of p14ARF, p15INK4b and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17:3771-3782.
61. Hruban RH, Shiu MH, Senie RT, Woodruff JM. Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer. 1990;66:1253-1265. (Pubitemid 20310668)
62. Meis JM, Enzinger FM, Martz KL, Neal JA. Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am J Surg Pathol. 1992;16:694-707.
63. Kourea HP, Bilsky MH, Leung DH, Lewis JJ, Woodruff JM. Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: A clinicopathologic study of 25 patients and 26 tumors. Cancer. 1998;82:2191-2203. (Pubitemid 28240826)
64. Loree TR, North JH, Jr., Werness BA, Nangia R, Mullins AP, Hicks WL, Jr. Malignant peripheral nerve sheath tumors of the head and neck: Analysis of prognostic factors. Otolaryngol Head Neck Surg. 2000;122:667-672. (Pubitemid 30333842)
65. Hagel C, Zils U, Peiper M, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol. 2007;82:187-192. (Pubitemid 46431864)
66. Trojanowski JQ, Kleinman GM, Proppe KH. Malignant tumors of nerve sheath origin. Cancer. 1980;46:1202-1212. (Pubitemid 10043491)
67. Arpornchayanon O, Hirota T, Itabashi M, et al. Malignant peripheral nerve tumors: A clinicopathological and electron microscopic study. Jpn J Clin Oncol. 1984;14:57-74.
68. Daimaru Y, Hashimoto H, Enjoji M. Malignant peripheral nerve-sheath tumors (malignant schwannomas). An immunohistochemical study of 29 cases. Am J Surg Pathol. 1985;9:434-444. (Pubitemid 15241143)
69. Lodding P, Kindblom LG, Angervall L. Epithelioid malignant schwannoma. A study of 14 cases. Virchows Arch A Pathol Anat Histopathol. 1986;409:433-451. (Pubitemid 16090125)
70. McCarron KF, Goldblum Jr. Plexiform neurofibroma with and without associated malignant peripheral nerve sheath tumor: A clinicopathologic and immunohistochemical analysis of 54 cases. Mod Pathol. 1998;11:612-617. (Pubitemid 28335138)
71. Casanova M, Ferrari A, Spreafico F, et al. Malignant peripheral nerve sheath tumors in children: A single-institution twenty-year experience. J Pediatr Hematol Oncol. 1999;21:509-513. (Pubitemid 30305985)
72. Minovi A, Basten O, Hunter B, Draf W, Bockmuhl U. Malignant peripheral nerve sheath tumors of the head and neck: Management of 10 cases and literature review. Head Neck. 2007;29:439-445. (Pubitemid 46732582)
73. Scheithauer BW, Erdogan S, Rodriguez FJ, et al. Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: A clinicopathologic study of 17 cases. Am J Surg Pathol. 2009;33: 325-338.
74. Moretti VM, Crawford EA, Staddon AP, Lackman RD, Ogilvie CM. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol-Cancer Clin Trials. 2011;34:417-421.
75. Ducatman BS, Scheithauer BW. Malignant peripheral nerve sheath tumors with divergent differentiation. Cancer. 1984;54: 1049-1057. (Pubitemid 14069823)
76. Bailet JW, Abemayor E, Andrews JC, Rowland JP, Fu YS, Dawson DE. Malignant nerve sheath tumors of the head and neck: A combined experience from two university hospitals. Laryngoscope. 1991;101: 1044-1049.
77. Shearer P, Parham D, Kovnar E, et al. Neurofibromatosis type I and malignancy: Review of 32 pediatric cases treated at a single institution. Med Pediatr Oncol. 1994;22:78-83.
78. Halling KC, Scheithauer BW, Halling AC, et al. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor: An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol. 1996;106:282-288. (Pubitemid 26309078)
79. Kluwe L, Friedrich RE, Peiper M, Friedman J, Mautner VF. Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors. Hum Mutat. 2003;22:420.
80. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005;65:205-211. (Pubitemid 41022362)
81. BrennerW, Friedrich RE, Gawad KA, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging. 2006;33:428-432.
82. Ingham S, Huson SM, Moran A, Wylie J, Leahy M, Evans DG. Malignant peripheral nerve sheath tumours in NF1: Improved survival in women and in recent years. Eur J Cancer. 2011;47:2723-2728.
83. Lothe RA, Slettan A, Saeter G, Brogger A, Borresen AL, Nesland JM. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J Neuropathol Exp Neurol. 1995;54:65-73.
84. Mechtersheimer G, Otano-Joos M, Ohl S, et al. Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer. 1999;25:362-369. (Pubitemid 29326143)
85. Plaat BE, Molenaar WM, Mastik MF, Hoekstra HJ, te Meerman GJ, van den Berg E. Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: Sporadic vs. neurofibromatosis-type-1-associated malignant schwannomas. Int J Cancer. 1999;83: 171-178. (Pubitemid 29449093)
86. Koga T, Iwasaki H, Ishiguro M, Matsuzaki A, Kikuchi M. Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis. J Pathol. 2002;197:98-107. (Pubitemid 34450169)
87. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol. 2003;21:4586-4591. (Pubitemid 46594031)
88. Holtkamp N, Reuss DE, Atallah I, et al. Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol. 2004;14:258-264. (Pubitemid 39095987)
89. Henderson SR, Guiliano D, Presneau N, et al. A molecular map of mesenchymal tumors. Genome Biol. 2005;6:R76.
90. Karube K, Nabeshima K, Ishiguro M, Harada M, Iwasaki H. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol. 2006;59: 160-165. (Pubitemid 43235581)
91. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 2006;66:2584-2591.
92. Francis P, Namløs HM, Muller C, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: Hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics. 2007;8:73.
93. Lévy P, Ripoche H, Laurendeau I, et al. Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res. 2007; 13:398-407. (Pubitemid 46225342)
94. Legius E, Dierick H, Wu R, et al. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer. 1994;10:250-255. (Pubitemid 24238432)
95. Leroy K, Dumas V, Martin-Garcia N, et al. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: A clinicopathologic and molecular study of 17 patients. Arch Dermatol. 2001; 137:908-913. (Pubitemid 32641650)
96. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest. 2001;81:833-844. (Pubitemid 32553405)
97. Taubert H, Wurl P, Bache M, et al. The p53 gene in soft tissue sarcomas: Prognostic value of DNA sequencing versus immunohistochemistry. Anticancer Res. 1998;18:183-187. (Pubitemid 28174704)
98. Watanabe T, Oda Y, Tamiya S, Kinukawa N, Masuda K, Tsuneyoshi M. Malignant peripheral nerve sheath tumours: High Ki67 labelling index is the significant prognostic indicator. Histopathology. 2001;39:187-197. (Pubitemid 34225046)
99. Lothe RA, Smith-Sorensen B, Hektoen M, et al. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer. 2001;30:202-206. (Pubitemid 32044602)
100. Agesen TH, Flørenes VA, Molenaar WM, et al. Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol. 2005;64:74-81. (Pubitemid 40189481)
101. Keizman D, Issakov J, Meller I, et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol. 2009;94:383-388.
102. Kobayashi C, Oda Y, Takahira T, et al. Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol. 2006;19:524-532.
103. Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: The emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol. 1999;155:1885-1891.
104. Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286: 2172-2176. (Pubitemid 129516295)
105. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type 1. Science. 1999;286:2176-2179.
106. Sørensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 1986;314:1010-1015. (Pubitemid 16113061)
107. Zöller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelveyear follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm Venereol. 1995;75:136-140.
108. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: An analysis using U.S. death certificates. Am J Hum Genet. 2001;68:1110-1118. (Pubitemid 32424410)
109. Ablon J. Living with Genetic Disorder: The Impact of Neurofibromatosis 1. Westport, CT: Auburn House, 1999.